| |
[摘要]：Tuberculosis caused by the bacterial pathogen Mycobacterium tuberculosis is a major human disease predominantly affecting the developing world. The complex lifestyle and cell wall of M. tuberculosis confer intrinsic resistance to most commonly used antibacteriols, often requiring the use of specialized antituberculosis drugs for the treatment of the disease. Coinfection with human immunodeficiency virus (HIV) and tuberculosis is cause for growing worldwide concern, and the emergence of multidrug-resistant and extensively drug-resistant tuberculosis further complicates the situation. Therefore, there is a demand for new antituberculosis drugs to combat the disease. Fortunately, characteristics that import uniqueness and complexity to the mycobacteriol cell wall also make it on attractive target for drug development. The current review describes some of the cell wall inhibitors under active development for the treatment of tuberculosis. |
|
